/MSCL.TO

MSCL.TO Stock - Satellos Bioscience Inc.

Q: What is the analyst price target for MSCL.TO?

Analyst price target information is not currently available for MSCL.TO.

Q: What is MSCL.TO's market cap?

Market capitalization information is not currently available for MSCL.TO.

Healthcare|Biotechnology|TSX

$0.66-2.94%

$0.02 (-2.94%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.73

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MSCL.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.71

52W High$0.94

52W Low$0.52

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-20,000	$-8,817,000	$-3,734,000	$-119,919	$-48,161
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-27,808,000	$-15,463,000	$-8,428,000	$-4,737,207	$-1,545,248
Net Income	$-28,099,000	$-15,889,000	$-11,322,000	$-15,505,652	$-1,578,530
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.24	$-0.18	$-0.32	$-0.64	$-0.05

Company Overview

Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Visit Website

Earnings History & Surprises

MSCL.TO

Beat Rate

31%

Last 13 quarters

Avg Surprise

-43.5%

EPS vs Estimate

Beats / Misses

4/8

1 met exactly

Latest EPS

$-0.04

Q4 2025

EPS Surprise History

Q1 24

-415.5%

$-0.07vs$-0.01

Q2 24

-20.0%

$-0.06vs$-0.05

Q3 24

+16.7%

$-0.05vs$-0.06

Q4 24

0.0%

$-0.05vs$-0.05

Q1 25

-25.0%

$-0.05vs$-0.04

Q2 25

+20.0%

$-0.04vs$-0.05

Q3 25

-7.5%

$-0.03vs$-0.03

Q4 25

-11.1%

$-0.04vs$-0.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 14, 2025	$-0.04	$-0.04	-11.1%	✗ MISS
Q3 2025	Aug 13, 2025	$-0.03	$-0.03	-7.5%	✗ MISS
Q2 2025	May 13, 2025	$-0.05	$-0.04	+20.0%	✓ BEAT
Q1 2025	Mar 26, 2025	$-0.04	$-0.05	-25.0%	✗ MISS
Q4 2024	Nov 13, 2024	$-0.05	$-0.05	0.0%	= MET
Q3 2024	Aug 12, 2024	$-0.06	$-0.05	+16.7%	✓ BEAT
Q2 2024	May 14, 2024	$-0.05	$-0.06	-20.0%	✗ MISS
Q1 2024	Mar 27, 2024	$-0.01	$-0.07	-415.5%	✗ MISS
Q3 2023	Sep 30, 2023	$-0.03	$-0.03	-17.2%	✗ MISS
Q2 2023	Jun 30, 2023	$-0.04	$-0.05	-32.1%	✗ MISS
Q1 2023	Mar 31, 2023	$-0.05	$-0.04	+25.9%	✓ BEAT
Q4 2022	Dec 31, 2022	$-0.05	$-0.12	-125.4%	✗ MISS
Q4 2022	Nov 23, 2022	$-0.07	$-0.05	+25.8%	✓ BEAT
Q3 2022	Sep 30, 2022	—	$-0.05	—	—

Frequently Asked Questions about MSCL.TO

What is MSCL.TO's current stock price?

Satellos Bioscience Inc. (MSCL.TO) is currently trading at $0.66 per share. The stock has moved -2.94% today.

What is the analyst price target for MSCL.TO?

No analyst price targets are currently available for this stock.

What sector is Satellos Bioscience Inc. in?

Satellos Bioscience Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.

What is MSCL.TO's market cap?

Satellos Bioscience Inc. has a market capitalization of $0.12 billion, making it a small-cap company.

Does MSCL.TO pay dividends?

No, Satellos Bioscience Inc. does not currently pay a dividend to shareholders.